Literature DB >> 19645588

New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.

Bo Wang1, Li-Ping Yang, Xiao-Zhuang Zhang, Shui-Qing Huang, Mark Bartlam, Shu-Feng Zhou.   

Abstract

To date, the crystal structures of at least 12 human CYPs (1A2, 2A6, 2A13, 2C8, 2C9, 2D6, 2E1, 2R1, 3A4, 7A1, 8A1, and 46A1) have been determined. CYP2D6 accounts for only a small percentage of all hepatic CYPs (< 2%), but it metabolizes approximately 25% of clinically used drugs with significant polymorphisms. CYP2D6 also metabolizes procarcinogens and neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1,2,3,4-tetrahydroquinoline, and indolealkylamines. Moreover, the enzyme utilizes hydroxytryptamines and neurosteroids as endogenous substrates. Typical CYP2D6 substrates are usually lipophilic bases with an aromatic ring and a nitrogen atom, which can be protonated at physiological pH. Substrate binding is generally followed by oxidation (5-7 A) from the proposed nitrogen-Asp301 interaction. A number of homology models have been constructed to explore the structural features of CYP2D6, while antibody studies also provide useful structural information. Site-directed mutagenesis studies have demonstrated that Glu216, Asp301, Phe120, Phe481, and Phe483 play important roles in determining the binding of ligands to CYP2D6. The structure of human CYP2D6 has been recently determined and shows the characteristic CYP fold observed for other members of the CYP superfamily. The lengths and orientations of the individual secondary structural elements in the CYP2D6 structure are similar to those seen in other human CYP2 members, such as CYP2C9 and 2C8. The 2D6 structure has a well-defined active-site cavity located above the heme group with a volume of approximately 540 A(3), which is larger than equivalent cavities in CYP2A6 (260 A(3)), 1A2 (375 A(3)), and 2E1 (190 A(3)), but smaller than those in CYP3A4 (1385 A(3)) and 2C8 (1438 A(3)). Further studies are required to delineate the molecular mechanisms involved in CYP2D6 ligand interactions and their implications for drug development and clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19645588     DOI: 10.1080/03602530903118729

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  43 in total

1.  Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

Authors:  An Wang; Uzen Savas; Mei-Hui Hsu; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

Review 2.  Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Authors:  Eric F Johnson; J Patrick Connick; James R Reed; Wayne L Backes; Manoj C Desai; Lianhong Xu; D Fernando Estrada; Jennifer S Laurence; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

Review 3.  Genetics and personalized medicine--a role in statin therapy?

Authors:  Jaideep Patel; Thura Abd; Roger S Blumenthal; Khurram Nasir; H Robert Superko
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

4.  Sex hormones regulate cerebral drug metabolism via brain miRNAs: down-regulation of brain CYP2D by androgens reduces the analgesic effects of tramadol.

Authors:  Jie Li; Mengmeng Xie; Xiaoshuang Wang; Xiufang Ouyang; Yu Wan; Guicheng Dong; Zheqiong Yang; Jing Yang; Jiang Yue
Journal:  Br J Pharmacol       Date:  2015-08-26       Impact factor: 8.739

Review 5.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

Review 6.  Structural diversity of eukaryotic membrane cytochrome p450s.

Authors:  Eric F Johnson; C David Stout
Journal:  J Biol Chem       Date:  2013-04-30       Impact factor: 5.157

Review 7.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

8.  IDSite: An accurate approach to predict P450-mediated drug metabolism.

Authors:  Jianing Li; Severin T Schneebeli; Joseph Bylund; Ramy Farid; Richard A Friesner
Journal:  J Chem Theory Comput       Date:  2011-11-08       Impact factor: 6.006

9.  Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.

Authors:  Amelia Nathania Dong; Nafees Ahemad; Yan Pan; Uma Devi Palanisamy; Beow Chin Yiap; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-26       Impact factor: 3.000

Review 10.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.